影响β-地中海贫血表型的遗传修饰作用

doi:10.16288/j.yczz.19-131

遗传 ›› 2019, Vol. 41 ›› Issue (8): 669-676.doi: 10.16288/j.yczz.19-131

影响β-地中海贫血表型的遗传修饰作用

张倩倩,商璇,林宛颖,徐湘民()

南方医科大学基础医学院医学遗传学教研室,广州 510800

收稿日期:2019-05-13 修回日期:2019-07-29 出版日期:2019-08-20 发布日期:2019-08-05
通讯作者: 徐湘民 E-mail:xixm@smu.edu.cn
作者简介:张倩倩,博士研究生,专业方向：遗传学。E-mail: zqq.smu@foxmail.com
基金资助:
国家重点研发计划(2018YFA0507803);国家自然科学基金项目资助(81870148)

Effect of genetic modifiers on the clinical severity of β-thalassemia

Zhang Qianqian,Shang Xuan,Lin Wanying,Xu Xiangmin()

Department of Medical Genetics, Southern Medical University, Guangzhou 510800, China

Received:2019-05-13 Revised:2019-07-29 Online:2019-08-20 Published:2019-08-05
Contact: Xu Xiangmin E-mail:xixm@smu.edu.cn
Supported by:
Supported by the National Key Research and Development Program of China(2018YFA0507803);The National Natural Science Foundation of China(81870148)

摘要/Abstract

摘要：

β-地中海贫血(β-地贫)是一种可致死、致残的遗传性血液病,临床上具有较宽泛的表型变异谱,在致病基因型相同或类似的情况下,患者的临床表型严重程度有很大的差异。探索影响β-地贫表型的遗传修饰因素是当前血液病及遗传病领域的研究热点和重点。本文从α-珠蛋白基因型和胎儿血红蛋白(Hb F)数量性状位点两个方面阐述了可加重或缓解β-地贫表型的遗传修饰因素,并着重介绍了调控γ-珠蛋白基因重激活的转录因子变异,以及β-珠蛋白基因簇顺式元件变异。最后,本文举例介绍了β-地贫遗传修饰的临床应用以及未来发展前景。

关键词: β-地中海贫血, 胎儿血红蛋白, 遗传修饰作用, 基因编辑

Abstract:

β-thalassemia (β-thal) is a fatal and disabling inherited blood disorder with diverse phenotypes. The same or similar genotype of β-thal can manifest variable clinical severities. It is the hotspot and emphasis in the field of hematopathy and genetic diseases to explore genetic modifiers that influence the phenotype of β-thal. This review illustrates the deteriorating and amelioratig modifiers from two aspects: genotypes of α-globin and quantitative trait locus of fetal hemoglobin (Hb F). Variations of transcription factors which reactive the γ-globin gene expression and β-globin cluster cis-acting elements were introduced emphatically. Finally, clinical applications and future development prospects of β-thal genetic modifiers are introduced by examples.

Key words: β-thalassemia, fetal hemoglobin, genetic modifier effects, gene editing

张倩倩,商璇,林宛颖,徐湘民. 影响β-地中海贫血表型的遗传修饰作用[J]. 遗传, 2019, 41(8): 669-676.

Zhang Qianqian,Shang Xuan,Lin Wanying,Xu Xiangmin. Effect of genetic modifiers on the clinical severity of β-thalassemia[J]. Hereditas(Beijing), 2019, 41(8): 669-676.

参考文献

[1]	Taher AT, Weatherall DJ, Cappellini MD . Thalassaemia. Lancet, 2018,391(10116):155-167.
[2]	Xiangmin Xu. Guidelines for thalassemia prevention and control programme. People’s Military Medical Press, 2011.
[2]	徐湘民 . 地中海贫血预防控制操作指南. 北京:人民军医出版社, 2011
[3]	Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors . Guidelines for the management of transfusion dependent thalassaemia (TDT) [Internet]. 3rd edition.Nicosia (CY): Thalassaemia International Federation; 2014.
[4]	Taher A, Vichinsky E, Musallam K, Cappellini MD Viprakasit V, authors Weatherall D, editor , Guidelines for the management of non transfusion dependent thalassaemia (NTDT) [Internet]. Nicosia,Cyprus: Thalassaemia International Federation; 2013.
[5]	Origa R . β-Thalassemia. Genet Med, 2017,19(6):609-619.
[6]	Shang X, Xu X . Update in the genetics of thalassemia: What clinicians need to know. Best Pract Res Cl Ob, 2017,9:3-15.
[7]	Mettananda S, Higgs DR . Molecular basis and genetic modifiers of thalassemia. Hematol Oncol Clin N, 2018,32(2):177-191.
[8]	Clark B, Shooter C, Smith F, Brawand D, Steedman L, Oakley M, Rushton P, Rooks H, Wang X, Drousiotou A, Kyrri A, Hadjigavriel M, Will A, Fisher C, Higgs DR, Phylipsen M, Harteveld C, Kleanthous M, Thein SL . Beta thalassaemia intermedia due to co-inheritance of three unique alpha globin cluster duplications characterised by next generation sequencing analysis. Br J Haematol, 2018,180(1):160-164.
[9]	Grandchamp B, Hetet G, Kannengiesser C, Oudin C, Beaumont C, Rodrigues-Ferreira S, Amson R, Telerman A, Nielsen P, Kohne E, Balser C, Heimpel H . A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. Blood, 2011,118(25):6660-6666.
[10]	Liu D, Yi S, Zhang X, Fang P, Zheng C, Lin L, Cai R, Ye Y, Zhou Y, Liang Y, Cheng F, Zhang X, Zhou W, Mohandas N, An X, Xu X . Human STEAP3 mutations with no phenotypic red cell changes. Blood, 2016,127(8):1067-1071.
[11]	Ragab SM, Badr EA, Ibrahim AS . Evaluation of glutathione-S-Transferase P1 polymorphism and its relation to bone mineral density in egyptian children and adolescents with Beta-thalassemia Major. Mediterr J Hematol Infect Dis, 2016,8(1):e2016004.
[12]	Mokhtar GM, Sherif EM, Habeeb NM, Abdelmaksoud AA, El-Ghoroury EA, Ibrahim AS, Hamed EM . Glutathione S-transferase gene polymorphism: relation to cardiac iron overload in egyptian patients with beta thalassemia major. Hematology, 2015,21(1):46-53.
[13]	Mettananda S, Gibbons RJ, Higgs DR . α-Globin as a molecular target in the treatment of β-thalassemia. Blood, 2015,125(24):3694-701.
[14]	Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, Busonero F, Maschio A, Albai G, Piras MG, Sestu N, Lai S, Dei M, Mulas A, Crisponi L, Naitza S, Asunis I, Deiana M, Nagaraja R, Perseu L, Satta S, Cipollina MD, Sollaino C, Moi P, Hirschhorn JN, Orkin SH, Abecasis GR, Schlessinger D, Cao A . Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA, 2008,105(5):1620-1625.
[15]	Liu D, Zhang X, Yu L, Cai R, Ma X, Zheng C, Zhou Y, Liu Q, Wei X, Lin L, Yan T, Huang J, Mohandas N, An X, Xu X . KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. Blood, 2014,124(5):803-811.
[16]	Guo XQ . Progress on genes related to fetal hemoglobin quantitative trait. Hereditas(Beijing), 2010,32(4):295-300.
[16]	郭晓强 . 胎儿血红蛋白数量性状相关基因的研究进展. 遗传, 2010,32(4):295-300.
[17]	Rujito L, Basalamah M, Siswandari W, Setyono J, Wulandari G, Mulatsih S, Sofro AS, Sadewa AH, Sutaryo S . Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: a study on β-thalassemia and hemoglobin E/β-thalassemia patients in indonesia. Hematol Oncol Stem Cell Ther, 2016,9(2):55-63.
[18]	Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur DS, Garcia SP, Luc S, Kurita R, Nakamura Y, Fujiwara Y, Maeda T, Yuan GC, Zhang F, Orkin SH, Bauer DE . BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015,527(7577):192-197.
[19]	Martyn GE, Wienert B, Yang L, Shah M, Norton LJ, Burdach J, Kurita R, Nakamura Y, Pearson RCM, Funnell APW, Quinlan KGR, Crossley M . Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet, 2018,50(4):498-503.
[20]	Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, Fisher C, Suciu M, Martyn GE, Norton LJ, Zhu C, Kurita R, Nakamura Y, Xu J, Higgs DR, Crossley M, Bauer DE, Orkin SH, Kharchenko PV, Maeda T . Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science, 2016,351(6270):285-289.
[21]	Perkins A, Xu X, Higgs DR, Patrinos GP, Arnaud L, Bieker JJ, Philipsen S , KLF1 Consensus Workgroup. Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood, 2016,127(15):1856-1862.
[22]	Lai Y, Chen Y, Chen B, Zheng H, Yi S, Li G, Wei H, He S, Zheng C . Genetic variants at BCL11A and HBS1L-MYB loci influence Hb F levels in Chinese Zhuang β-Thalassemia intermedia patients. Hemoglobin, 2016,40(6):405-410.
[23]	Sankaran VG, Menne TF, Šćepanović D, Vergilio JA, Ji P, Kim J, Thiru P, Orkin SH, Lander ES, Lodish HF . MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA, 2011,108(4):1519-1524.
[24]	Chen Z, Tang H, Qayyum R, Schick UM, Nalls MA, Handsaker R, Li J, Lu Y, Yanek LR, Keating B, Meng Y, van Rooij FJ, Okada Y, Kubo M, Rasmussen-Torvik L, Keller MF, Lange L, Evans M, Bottinger EP, Linderman MD, Ruderfer DM, Hakonarson H, Papanicolaou G, Zonderman AB, Gottesman O; BioBank Japan Project; CHARGE Consortium, Thomson C, Ziv E, Singleton AB, Loos RJ, Sleiman PM, Ganesh S, McCarroll S, Becker DM, Wilson JG, Lettre G, Reiner AP . Genome-wide association analysis of red blood cell traits in african americans: the COGENT Network. Hum Mol Genet, 2013,22(12):2529-2538.
[25]	Liu RR, Wang MY, Lai YR . Analysis of Gγ-158(C→T) polymorphism in hemoglobin E/β-thalassemia major in Southern China. J Hematol Oncol, 2010,3:29.
[26]	Mtatiro SN, Makani J, Mmbando B, Thein SL, Menzel S, Cox SE . Genetic variants at HbF-modifier loci moderate anemia and leukocytosis in sickle cell disease in tanzania. Am J Hematol, 2015,90(1):E1-4.
[27]	Wienert B, Martyn GE, Funnell APW, Quinlan KGR, Crossley M . Wake-up sleepy gene: reactivating fetal globin for β-hemoglobinopathies. Trends Genet, 2018,34(12):927-940.
[28]	Martyn GE, Wienert B, Kurita R, Nakamura Y, Quinlan KGR, Crossley M . A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site. Blood, 2019,133(8):852-856.
[29]	Joly P, Lacan P, Garcia C, Meley R, Pondarré C, Francina A . A novel deletion/insertion caused by a replication error in the β-globin gene locus control region. Hemoglobin, 2011,35(4):316-322.
[30]	Kim YW, Kim A . Deletion of transcription factor binding motifs using the CRISPR/spCas9 system in the β-globin LCR. Bioscience Rep, 2017, 37(4): BSR20170976.
[31]	Ju JY, Zhao Q . Regulation of γ-globin gene expression and its clinical applications. Hereditas(Beijing), 2018,40(6):429-444.
[31]	鞠君毅, 赵权 . γ-珠蛋白基因表达调控机制与临床应用. 遗传, 2018,40(6):429-444.
[32]	Ley TJ, Anagnou NP, Noguchi CT, Schechter AN, DeSimone J, Heller P, Nienhuis AW . DNA methylation and globin gene expression in patients treated with 5-azacytidine. Prog Clin Biol Res, 1983,134:457-474.
[33]	Chen D, Zuo Y, Zhang X, Ye Y, Bao X, Huang H, Tepakhan W, Wang L, Ju J, Chen G, Zheng M, Liu D, Huang S, Zong L, Li C, Chen Y, Zheng C, Shi L, Zhao Q, Wu Q, Fucharoen S, Zhao C, Xu X . A genetic variant ameliorates β-Thalassemia severity by epigenetic-mediated elevation of human fetal hemoglobin expression. Am J Hum Genet, 2017,101(1):130-138.
[34]	Mettananda S, Fisher CA, Sloane-Stanley JA, Taylor S, Oppermann U, Gibbons RJ, Higgs DR . Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia. Haematologica, 2017,102(3):e80-e84.
[35]	Dai Y, Chen T, Ijaz H, Cho EH, Steinberg MH . SIRT1 activates the expression of fetal hemoglobin genes. Am J Hematol, 2017,92(11):1177-1186.
[36]	Danjou F, Francavilla M, Anni F, Satta S, Demartis FR, Perseu L, Manca M, Sollaino MC, Manunza L, Mereu E, Marceddu G, Pissard S, Joly P, Thuret I, Origa R, Borg J, Forni GL, Piga A, Lai ME, Badens C, Moi P, Galanello R . A genetic score for the prediction of beta-thalassemia severity. Haematologica, 2015,100(4):452-457.
[37]	Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, Clement K, Cole MA, Luk K, Baricordi C, Shen AH, Ren C, Esrick EB, Manis JP, Dorfman DM, Williams DA, Biffi A, Brugnara C, Biasco L, Brendel C, Pinello L, Tsai SQ, Wolfe SA, Bauer DE . Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med, 2019,25(5):776-783.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

影响β-地中海贫血表型的遗传修饰作用

Effect of genetic modifiers on the clinical severity of β-thalassemia

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨新萍,于媛,许操. 重新设计与快速驯化创造新型作物[J]. 遗传, 2019, 41(9): 827-835.
[2]	牛煦然,尹树明,陈曦,邵婷婷,李大力. 基因编辑技术及其在疾病治疗中的研究进展[J]. 遗传, 2019, 41(7): 582-598.
[3]	欧浩,李国玲,王豪强,黄广燕,蔡更元,李紫聪,吴珍芳,张献伟. MEK抑制剂PD0325901显著提高猪胎儿成纤维细胞ssODN介导的HDR效率[J]. 遗传, 2019, 41(4): 327-336.
[4]	任云晓, 肖茹丹, 娄晓敏, 方向东. 基因编辑技术及其在基因治疗中的应用[J]. 遗传, 2019, 41(1): 18-27.
[5]	黄耀强,李国玲,杨化强,吴珍芳. 基因编辑猪在生物医学研究中的应用[J]. 遗传, 2018, 40(8): 632-646.
[6]	鞠君毅,赵权. γ-珠蛋白基因表达调控机制与临床应用[J]. 遗传, 2018, 40(6): 429-444.
[7]	刘佳伟,洪涛,秦鑫,梁英民,张萍. β-血红蛋白病基因组编辑治疗的研究进展[J]. 遗传, 2018, 40(2): 95-103.
[8]	辛高伟, 胡熙璕, 王克剑, 王兴春. Cas9蛋白变体VQR高效识别水稻NGAC前间区序列邻近基序[J]. 遗传, 2018, 40(12): 1112-1119.
[9]	陈一欧, 宝颖, 马华峥, 伊宗裔, 周卓, 魏文胜. 基因编辑技术及其在中国的研究发展[J]. 遗传, 2018, 40(10): 900-915.
[10]	叶宇华,张倩倩,钟建美,黎倚红,张立,喻秋霞,徐湘民. 人类珠蛋白相关基因上游开放阅读框的变异分析[J]. 遗传, 2017, 39(3): 232-240.
[11]	马丽, 陈红岩, 朱化星, 李威, 卢大儒. 利用锁核酸化学偶联FokⅠ核酸酶靶向切割HBV基因的体外实验[J]. 遗传, 2016, 38(4): 350-359.
[12]	王大勇, 马宁, 惠洋, 高旭. CRISPR/Cas9基因组编辑技术在癌症研究中的应用[J]. 遗传, 2016, 38(1): 1-8.
[13]	殷利眷,胡斯奇,郭斐. CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用[J]. 遗传, 2015, 37(5): 412-418.
[14]	刘改改,李爽,韦余达,张永贤,丁秋蓉. 利用CRISPR/Cas9技术对人多能干细胞进行高效基因组编辑[J]. 遗传, 2015, 37(11): 1167-1173.
[15]	李晨, 楼慧强. 酵母基因编辑技术：从单基因操作到基因组重建[J]. 遗传, 2015, 37(10): 1021-1028.